GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (OTCPK:LOVFF) » Definitions » ROC %

Cannara Biotech (Cannara Biotech) ROC % : -6.05% (As of Feb. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Cannara Biotech's annualized return on capital (ROC %) for the quarter that ended in Feb. 2024 was -6.05%.

As of today (2024-05-04), Cannara Biotech's WACC % is 5.57%. Cannara Biotech's ROC % is 9.53% (calculated using TTM income statement data). Cannara Biotech generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Cannara Biotech ROC % Historical Data

The historical data trend for Cannara Biotech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech ROC % Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
ROC %
Get a 7-Day Free Trial -36.28 -27.94 0.50 5.43 10.42

Cannara Biotech Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.41 14.92 19.77 10.87 -6.05

Cannara Biotech ROC % Calculation

Cannara Biotech's annualized Return on Capital (ROC %) for the fiscal year that ended in Aug. 2023 is calculated as:

ROC % (A: Aug. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Aug. 2022 ) + Invested Capital (A: Aug. 2023 ))/ count )
=8.919 * ( 1 - 0% )/( (80.416 + 90.721)/ 2 )
=8.919/85.5685
=10.42 %

where

Cannara Biotech's annualized Return on Capital (ROC %) for the quarter that ended in Feb. 2024 is calculated as:

ROC % (Q: Feb. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2023 ) + Invested Capital (Q: Feb. 2024 ))/ count )
=-5.808 * ( 1 - 0% )/( (94.233 + 97.636)/ 2 )
=-5.808/95.9345
=-6.05 %

where

Note: The Operating Income data used here is four times the quarterly (Feb. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannara Biotech  (OTCPK:LOVFF) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cannara Biotech's WACC % is 5.57%. Cannara Biotech's ROC % is 9.53% (calculated using TTM income statement data). Cannara Biotech generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cannara Biotech ROC % Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech (Cannara Biotech) Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .